Moneycontrol PRO
Open App

5-day coronavirus treatment to cost no more than Rs 30,000: Hetero

Cipla has not disclosed the pricing of the drug, Hetero said it will supply its version of remdesivir at Rs 5,000- Rs 6,000 per vial.

June 22, 2020 / 10:27 PM IST

Cipla and Hetero, on June 21, said they had launched generic versions of remdesivir.

Both the companies received regulatory approval of remedesivir from the Drug Controller General of India (DCGI), on June 20, for restricted emergency use as part of the accelerated approval process considering the urgent and unmet medical need.

Cipla launched its verion of remedesivir 100 mg vial (injectable) under brand name CIPREMI, while Hetero launched the product under the brand name COVIFOR.

Cipla has not disclosed the pricing of the drug, Hetero said it would supply its version of remdesivir at Rs 5,000- Rs 6,000 per vial.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Hetero has said it wants to ensure the five-day treatment or six vials should cost not more than Rs 30,000 per patient.

"As part of a risk management plan, Cipla will provide training on use of the drug, informed patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV clinical trial on Indian patients," Cipla said in a statement.

Also Read: Remdesivir may be 'widely available' in India by June-end

The company said it would be commercialising remdesivir through its own facilities and partnered sites.

"The drug will be supplied through government and open market channels, to ensure equitable distribution," the company added.

Sources say Cipla has partnered with BDR Pharma to manufacture the drug.

“We will continue to collaborate with all stakeholders in the healthcare ecosystem towards providing access to such promising treatments in furtherance with our belief that no patient should be denied access to life-saving treatments,” Umang Vohra, MD and Global CEO, Cipla said.

Hetero said it had enough stocks to supply to the present needs of the country

"We can ensure that the product is immediately made available to patients across the country," said B Partha Saradhi Reddy, Chairman - Hetero Group of Companies.

Also Read: Check advisory from Ministry of Health and Family Welfare

In May, Gilead Sciences entered into voluntary non-exclusive license with Cipla, Hetero, Jubilant Life Sciences, Mylan and Pakistani company to manufacture and market remdesivir in 127 countries including India. Gilead later entered similar agreement with Zydus Cadila and Dr Reddy's.

The Indian health ministry protocol says the Gilead's antiviral drug may be considered in patients with moderate disease or those on oxygen.

The protocol advises giving the drug against people with liver disease, kidney failure, pregnant or lactating women, and children under 12 years.

Remdesivir usage is for five days, 200 mg IV (intravenous) on day 1 followed by 100 mg IV daily for five days.
Viswanath Pilla is a business journalist with 14 years of reporting experience. Based in Mumbai, Pilla covers pharma, healthcare and infrastructure sectors for Moneycontrol.
first published: Jun 21, 2020 08:34 pm
ISO 27001 - BSI Assurance Mark